
NeuroTechCompanies
Get flash to fully experience Pearltrees
The Company's portfolio of product candidates includes NT-501, currently in late-stage clinical development for geographic atrophy (GA) associated with atrophic (dry) age-related macular degeneration (AMD) and retinitis pigmentosa (RP), and NT-503, currently in pre-clinical development for wet AMD. In 2009, Neurotech completed three Phase 2 clinical studies of NT-501 for the treatment GA and RP. In the GA study the Company announced positive results, including the achievement of human proof of concept. In two RP studies, the Company announced consistent and positive biological effects on photoreceptors. All of Neurotech's development programs are based on the Company's proprietary Encapsulated Cell Technology (ECT). ECT uniquely enables the controlled, continuous delivery of biologics directly to the back of the eye, thereby overcoming a major obstacle in the treatment of retinal disease.
Neurotech
MegaMatcher Accelerator – biometric solution that can match 200 million irises per second or 100 million fingerprints per second on the server-side of a large-scale AFIS or multi-biometric system. NVeiler Video Filter – a plug-in for VirtualDub that automatically detects faces in a frame, tracks the faces in subsequent frames and hides the faces by using pixelation effect. Speaker , iris and object recognition technologies for Android -based mobile and embeded devices are now available. Also, the existing products are improved.

